Capricor Therapeutics Inc


Prices are adjusted according to historical splits.

Capricor Therapeutics Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$105.82 million
Book Value:
Revenue TTM:
$2.55 million
Operating Margin TTM:
Gross Profit TTM:
$1.75 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Capricor Therapeutics Inc had its IPO on 2007-02-13 under the ticker symbol CAPR.

The company operates in the Healthcare sector and Biotechnology industry. Capricor Therapeutics Inc has a staff strength of 74 employees.

Stock update

Shares of Capricor Therapeutics Inc opened at $4.13 at the start of the last trading session i.e. 2023-03-24.

The stocks traded within a range of $4.06 - $4.27, and closed at $4.12.

This is a -1.67% slip from the previous day's closing price.

A total volume of 83,257 shares were traded at the close of the day’s session.

In the last one week, shares of Capricor Therapeutics Inc have slipped by -9.65%.

Capricor Therapeutics Inc's Key Ratios

Capricor Therapeutics Inc has a market cap of $105.82 million, indicating a price to book ratio of 6.4959 and a price to sales ratio of 61.6934.

In the last 12-months Capricor Therapeutics Inc’s revenue was $2.55 million with a gross profit of $1.75 million and an EBITDA of $-29164252. The EBITDA ratio measures Capricor Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Capricor Therapeutics Inc’s operating margin was -1163.93% while its return on assets stood at -40.6% with a return of equity of -134.49%.

In Q4, Capricor Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.

Capricor Therapeutics Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-1.09 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Capricor Therapeutics Inc’s profitability.

Capricor Therapeutics Inc stock is trading at a EV to sales ratio of 35.4213 and a EV to EBITDA ratio of -2.0433. Its price to sales ratio in the trailing 12-months stood at 61.6934.

Capricor Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$50.09 million
Total Liabilities
$23.59 million
Operating Cash Flow
Capital Expenditure
$1.10 million
Dividend Payout Ratio

Capricor Therapeutics Inc ended 2023 with $50.09 million in total assets and $0 in total liabilities. Its intangible assets were valued at $50.09 million while shareholder equity stood at $11.79 million.

Capricor Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $23.59 million in other current liabilities, 25241.00 in common stock, $-137079811.00 in retained earnings and $0 in goodwill. Its cash balance stood at $9.60 million and cash and short-term investments were $41.42 million. The company’s total short-term debt was $682,039 while long-term debt stood at $3.38 million.

Capricor Therapeutics Inc’s total current assets stands at $42.89 million while long-term investments were $0 and short-term investments were $31.82 million. Its net receivables were $547580.00 compared to accounts payable of $4.83 million and inventory worth $0.

In 2023, Capricor Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $1.10 million.

Comparatively, Capricor Therapeutics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Capricor Therapeutics Inc stock is currently trading at $4.12 per share. It touched a 52-week high of $6.58 and a 52-week low of $6.58. Analysts tracking the stock have a 12-month average target price of $15.

Its 50-day moving average was $4.37 and 200-day moving average was $4.7 The short ratio stood at 4.2 indicating a short percent outstanding of 0%.

Around 264.3% of the company’s stock are held by insiders while 1092% are held by institutions.

Frequently Asked Questions About Capricor Therapeutics Inc

The stock symbol (also called stock or share ticker) of Capricor Therapeutics Inc is CAPR

The IPO of Capricor Therapeutics Inc took place on 2007-02-13

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price
Imara Inc (IMRA)


Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.


10865 Road to the Cure, San Diego, CA, United States, 92121